Haemonetics Corporation HAE
120.16 USD -0.21 (-0.17%)
Regular-session close
120.16 0.00 0.00%
After hours · Nov 20, 5:31 PM ET
119.68 Day range 122.00
52.24 52-week range 127.42
- YTD
- +49.92%
- 1 year
- +59.96%
Benzinga news
benzinga.com Citizens Maintains Market Outperform on Haemonetics, Raises Price Target to $144 Citizens analyst Daniel Stauder maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $115 to $144.
benzinga.com This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated coverage on UCTT, DNLI, HAE, MTRI and ADI, assigning ratings from Equal-Weight to Buy and targets of $33-$505.benzinga.com Jefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150 Jefferies analyst Young Li initiates coverage on Haemonetics (NYSE:HAE) with a Buy rating and announces Price Target of $150.
benzinga.com Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149 Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $123 to $149.
benzinga.com Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145 Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $140 to $145.
benzinga.com BTIG Maintains Buy on Haemonetics, Raises Price Target to $142 BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $130 to $142.
benzinga.com Haemonetics Q2 2027 Earnings Call Transcript Haemonetics (NYSE:HAE) reported second-quarter financial results on Thursday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com Haemonetics Raises FY2027 Sales Guidance from $1.401B-$1.441B to $1.441B-$1.481B vs $1.418B Est Haemonetics (NYSE:HAE) raises FY2027 sales outlook from $1.401 billion-$1.441 billion to $1.441 billion-$1.481 billion vs $1.418 billion estimate.
benzinga.com Haemonetics Q2 Adj. EPS $1.35 Beats $1.29 Estimate, Sales $357.759M Beat $345.003M Estimate Haemonetics (NYSE:HAE) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.29 by 4.65 percent. This is a 6.3 percent increase over earnings of $1.27 per…
